Retatrutide Triple-Agonist Signalling: GLP-1, GIP and Glucagon

Retatrutide, also known as LY3437943, is an investigational peptide designed to activate three metabolically relevant receptors: the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon receptor (GCGR). This combined activity is why retatrutide is described as a triple agonist.

Unlike single-receptor agonists, which primarily engage one signalling pathway, retatrutide was engineered to bring together incretin and glucagon receptor activity within a single molecule. Research into this approach is based on the hypothesis that GLP-1, GIP and glucagon signalling may provide complementary effects on glucose regulation, energy intake and broader metabolic processes.

The important distinction for researchers is that receptor activity and clinical outcomes represent different levels of evidence. Demonstrating that LY3437943 activates GLP-1R, GIPR and GCGR establishes its pharmacological mechanism; it does not, by itself, establish a particular clinical effect.

What Is the Retatrutide Mechanism of Action?

The mechanism of action of retatrutide is based on simultaneous agonism of three G-protein-coupled receptors (GPCRs):

• GLP-1R: involved in incretin signalling, glucose-dependent insulin secretion and pathways associated with appetite and gastrointestinal regulation.
• GIPR: involved in nutrient-responsive insulin secretion and broader metabolic signalling.
• GCGR: involved in hepatic glucose mobilisation, substrate metabolism and other glucagon-mediated metabolic processes.

All three receptors can engage intracellular signalling pathways involving cyclic adenosine monophosphate (cAMP), although receptor distribution, downstream responses and physiological effects differ.

Early pharmacological characterisation of LY3437943 demonstrated agonist activity at all three receptors, with balanced activity at GLP-1R and GCGR and greater activity at GIPR in the experimental systems evaluated. Subsequent structural research has provided additional insight into how the same peptide can interact with each receptor.

This multi-receptor profile is the central feature being investigated in retatrutide research.

For a broader introduction to laboratory peptides and how research-use compounds differ from therapeutic products, see What Are Research Peptides?.

GLP-1 Receptor Signalling

GLP-1 is an incretin hormone released in response to nutrient intake. Activation of GLP-1R can increase intracellular cAMP and influence pancreatic beta-cell signalling, particularly glucose-dependent insulin secretion.

GLP-1 signalling is also involved in central and gastrointestinal pathways associated with food intake and gastric motility. These biological functions have made GLP-1R an established target in metabolic pharmacology.

Within the retatrutide mechanism of action, however, GLP-1R activity should not be considered in isolation. LY3437943 is not simply a GLP-1 receptor agonist. Its pharmacological design incorporates GIPR and GCGR activity as well.

This distinction is important when interpreting experimental findings. If a biological response occurs after exposure to retatrutide, receptor-specific experiments are required to determine how much of that response is attributable to GLP-1R signalling versus activity at the other two receptors.

Therefore, GLP-1R activation provides one component of retatrutide’s pharmacological profile rather than a complete explanation of its biological effects.

GIP Receptor Signalling

GIP, or glucose-dependent insulinotropic polypeptide, is another nutrient-responsive hormone. GIPR is expressed in tissues involved in metabolic regulation and participates in incretin signalling, including nutrient-stimulated insulin secretion.

Research into combined GIPR and GLP-1R agonism has established interest in using multiple incretin pathways to modify metabolic signalling. Retatrutide extends this concept further by adding GCGR activity.

The role of GIPR in the retatrutide triple agonist profile is therefore an important area of pharmacological investigation. Researchers can examine whether GIPR activation modifies signalling initiated through GLP-1R or interacts with glucagon-associated pathways.

At the molecular level, this means that the three receptor systems should not necessarily be treated as independent switches. Receptor abundance, tissue distribution, intracellular signalling and pharmacological potency can all influence the integrated response.

As a result, demonstrating GIPR agonism is evidence of target engagement, while any subsequent physiological or clinical outcome requires separate investigation.

Glucagon Receptor Signalling

The third component of the GLP-1 GIP glucagon receptor profile is GCGR agonism.

Glucagon has a well-established role in maintaining glucose availability during fasting. Its actions include stimulating hepatic glycogenolysis and gluconeogenesis and influencing substrate metabolism.

Glucagon signalling has also attracted interest in metabolic research because of its potential relationship with lipid metabolism and energy expenditure. This provides an important rationale for including GCGR activity in a multi-receptor molecule.

Preclinical work with LY3437943 suggested that GCGR-mediated effects on energy expenditure could complement reductions in energy intake associated with GLP-1R and GIPR signalling.

However, this should be interpreted as a mechanistic research hypothesis, not as proof that every observed metabolic outcome in humans is caused by GCGR activation.

The contribution of glucagon receptor signalling to the overall pharmacology of retatrutide remains an important research question. In particular, researchers need to distinguish direct receptor-mediated effects from downstream adaptations that occur after exposure to a multi-receptor agonist.

Why Combine GLP-1, GIP and Glucagon?

The scientific rationale for triple agonism is based on the possibility that these receptor pathways may provide complementary metabolic signals.

A simplified representation is:

GLP-1R → incretin and glucose-regulatory signalling

GIPR → incretin and metabolic signalling

GCGR → hepatic and broader catabolic metabolic signalling

Retatrutide integrates these activities into a single peptide.

The objective is not simply to activate three receptors simultaneously, but to investigate whether their combined pharmacology produces a biological profile that differs from single- or dual-receptor approaches.

Preclinical research provided early support for this concept. In obese mouse models, LY3437943 reduced body weight and improved glycaemic measures. The researchers proposed that reduced calorie intake associated with GLP-1R and GIPR activity could be complemented by GCGR-associated increases in energy expenditure.

This is an important mechanistic distinction: the observed outcome is the result of an integrated pharmacological system, rather than evidence that one receptor independently produces the entire response.

From Receptor Biology to Biological Outcomes

For researchers evaluating retatrutide, evidence can be considered across several levels.

Molecular and cellular research

At the first level, studies investigate receptor binding, receptor activation and intracellular signalling.

These experiments can help establish whether LY3437943 engages GLP-1R, GIPR and GCGR and how receptor activation affects downstream pathways such as cAMP signalling.

This establishes pharmacological activity. It does not establish clinical efficacy.

Preclinical research

Animal models allow researchers to examine the integrated effects of multi-receptor activation at the whole-organism level.

The initial development research reported effects on body weight and glycaemic control in obese mice and used these findings to support the hypothesis that the three receptor pathways could provide complementary metabolic effects.

Preclinical findings are useful for understanding mechanism and generating hypotheses, but they cannot automatically be extrapolated to humans.

Human clinical research

Human trials represent a separate evidence category.

Early clinical research with LY3437943 investigated pharmacokinetics, pharmacodynamics and tolerability in people with type 2 diabetes. A phase 1b study subsequently reported reductions in glucose and body weight while characterising the compound’s pharmacological profile.

A phase 2 trial also evaluated retatrutide in people with type 2 diabetes, while another phase 2 study investigated the compound in adults with overweight or obesity.

Clinical-trial registries such as the Australian New Zealand Clinical Trials Registry can be used to review registered retatrutide studies and their reported study details. ClinicalTrials.gov provides another source for reviewing registered retatrutide studies, including study status, interventions and outcome measures where available.

These studies demonstrate progression from receptor-level and preclinical research into human clinical investigation. They should nevertheless be interpreted separately from laboratory studies using research-use-only materials.

Why Receptor Activity Does Not Equal Clinical Outcome

One of the most important considerations when interpreting the retatrutide mechanism of action is avoiding a direct jump from receptor activation to a claimed clinical effect.

A receptor can be activated without producing an identical response in every tissue or physiological setting. Factors that can influence the observed response include:

• receptor expression and distribution;
• receptor potency and efficacy;
• intracellular signalling pathways;
• tissue-specific biology;
• pharmacokinetic exposure;
• receptor desensitisation and internalisation;
• physiological and metabolic state;
• interactions between signalling pathways.

For a triple agonist, these variables become even more relevant because three receptor systems are being engaged simultaneously.

Consequently, researchers should avoid statements such as ‘GLP-1 causes X, GIP causes Y and glucagon causes Z, therefore retatrutide produces X + Y + Z.’ Such a model oversimplifies multi-receptor pharmacology.

A more appropriate interpretation is that retatrutide generates an integrated signalling profile, and experimental studies are required to determine how each receptor contributes to the resulting phenotype.

Retatrutide and Energy Expenditure

GCGR activity is particularly relevant to research investigating energy expenditure.

Glucagon signalling has been studied for its effects on hepatic metabolism, substrate utilisation and energy expenditure. In the original development work for LY3437943, researchers proposed that GCGR-mediated effects could complement GLP-1R- and GIPR-associated effects on energy intake.

However, the relationship between glucagon receptor activation and energy expenditure is more complex than simply describing glucagon as a ‘metabolism-boosting’ pathway.

Energy expenditure is influenced by multiple physiological processes, and the contribution of individual receptor pathways needs to be investigated experimentally.

This is particularly important when moving from animal studies to human research. A metabolic effect observed in an animal model does not establish that the same mechanism quantitatively explains an outcome in humans.

For researchers, the more scientifically defensible position is therefore that GCGR agonism is a mechanistic component of retatrutide being investigated for its potential contribution to whole-body metabolic responses.

What Makes LY3437943 Different From Single-Receptor Agonists?

The defining characteristic of LY3437943 is its combinatorial receptor activity.

A single GLP-1R agonist primarily provides GLP-1 receptor signalling. A dual GIPR/GLP-1R agonist adds GIPR activity. Retatrutide extends the multi-receptor concept by incorporating GCGR agonism as a third pharmacological component.

Structural research has provided evidence of retatrutide interacting with GLP-1R, GIPR and GCGR while adopting receptor-specific molecular interactions.

This makes retatrutide relevant to researchers studying multi-receptor pharmacology, incretin biology and metabolic signalling.

What Researchers Should Consider When Evaluating Retatrutide Research Material

Mechanistic research requires clear separation between a compound’s identity and its use in clinical development.

Retatrutide has been investigated in registered clinical studies, but clinical-trial material and research-use-only material should not be treated as interchangeable. Formulation, manufacturing controls, analytical characterisation, storage requirements and intended use can differ.

For laboratory research, researchers and research buyers should therefore consider documentation supporting:

• compound identity;
• analytical characterisation;
• lot-specific quality information;
• certificate of analysis (COA);
• stated research-use status;
• appropriate handling and storage information.

The Retatrutide research product page provides product-specific information, while the Certificate of Analysis resources can be consulted for available analytical documentation.

The broader Metabolic Research area provides additional context for research involving metabolic pathways and related compounds.

Research-use disclaimer

Retatrutide is an investigational compound. Research-use-only retatrutide materials are intended solely for laboratory research and are not for human or veterinary use. The information provided is for scientific and educational purposes and does not constitute medical advice, treatment guidance, dosing guidance, injection instructions, cycling advice, or a recommendation regarding efficacy or safety. Clinical-trial materials and findings should not be interpreted as establishing suitability of research-use-only products for human use.